Literature DB >> 8536531

Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies.

C Bergmann1, A Sarem-Aslani, D Ratge, P Fritz, S Walker, H Wisser, U Klotz.   

Abstract

In peptic ulcer patients with adequate (AR; N = 16) and inadequate response (IR; N = 20) to H2-receptor antagonists, the presence of parietal cell cAMP-stimulating autoantibodies was studied. Serum Ig fractions from these patients and 10 control subjects were examined to test whether they could stimulate cAMP production in a gastric cell line model. The human cell line HGT-1 was found to be a sensitive in vitro model for the cAMP stimulation assay as histamine (10 microM) increased by 11-fold the production of cAMP. Neither IgG (4 mg/ml) nor IgG-free Ig fractions (1 mg/ml) isolated from the blood of AR or IR affected cAMP production in the HGT-1 cells. The results obtained with the cAMP stimulation assay were confirmed by indirect immunofluorescence measurements based on frozen sections of rat stomach and kidney. No specific staining of rat parietal cells could be observed with patient sera. In addition, human gastric biopsies of the oxyntic mucosa from the same patients were studied for immunoreactive cell populations to assess organ-specific autoimmune processes. Biopsy specimens from AR and IR showed increased lymphocytic infiltrates, usually associated with gastritis. However, no significant differences in location of various cell populations between AR and IR could be observed. Our findings do not support a recent hypothesis that poor response to treatment with H2-receptor antagonists is due to the presence of autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536531     DOI: 10.1007/bf02220460

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Peptic ulcer disease: absence of antibodies stimulating the histamine sensitive adenylate cyclase of gastric mucosal cells.

Authors:  P Burman; S Mårdh; L Lööf; J Naesdal; F A Karlsson
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

2.  Frequent non-response to histamine H2-receptor antagonists in cirrhotics.

Authors:  S Walker; D R Krishna; U Klotz; J C Bode
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

3.  Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).

Authors:  M J Collen; V J Stanczak; C A Ciarleglio
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

4.  Secretagogue globulins in the blood of duodenal ulcer patients.

Authors:  S Dobi; G Petrányi
Journal:  Acta Med Acad Sci Hung       Date:  1973

5.  [Treatment failure of cimetidine in duodenal ulcer (author's transl)].

Authors:  R Gugler; H G Rohner; A A Somogyi
Journal:  Dtsch Med Wochenschr       Date:  1982-07-09       Impact factor: 0.628

6.  Gastric parietal cell antibodies: demonstration by immunofluorescence of their reactivity with surface of the gastric parietal cells.

Authors:  C Masala; G Smurra; M A Di Prima; M A Amendolea; D Celestino; F Salsano
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

7.  Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.

Authors:  D W Burget; S G Chiverton; R H Hunt
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

8.  Role of a secretagogue immunoglobulin in gastric acid secretion.

Authors:  S Dobi; B Lenkey
Journal:  Acta Physiol Acad Sci Hung       Date:  1982

9.  Expression of HLA-DR antigens on epithelium associated with lymphoid tissue in the human gastrointestinal tract.

Authors:  J Spencer; T Finn; P G Isaacson
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

10.  Pharmacology of histamine H2 receptor antagonists in the human gastric cancer cell line HGT-1. Structure-activity relationship of isocytosine-furan and imidazole derivatives related to cimetidine.

Authors:  S Emami; C Gespach
Journal:  Biochem Pharmacol       Date:  1986-06-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.